Advertisement

Topics

PubMed Journals Articles About "Global Chinese Imatinib Mesylate Industry 2017 Market Research" RSS

06:09 EST 16th December 2018 | BioPortfolio

Global Chinese Imatinib Mesylate Industry 2017 Market Research PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Global Chinese Imatinib Mesylate Industry 2017 Market Research articles that have been published worldwide.

More Information about "Global Chinese Imatinib Mesylate Industry 2017 Market Research" on BioPortfolio

We have published hundreds of Global Chinese Imatinib Mesylate Industry 2017 Market Research news stories on BioPortfolio along with dozens of Global Chinese Imatinib Mesylate Industry 2017 Market Research Clinical Trials and PubMed Articles about Global Chinese Imatinib Mesylate Industry 2017 Market Research for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Global Chinese Imatinib Mesylate Industry 2017 Market Research Companies in our database. You can also find out about relevant Global Chinese Imatinib Mesylate Industry 2017 Market Research Drugs and Medications on this site too.

Showing "Global Chinese Imatinib mesylate Industry 2017 Market Research" PubMed Articles 1–25 of 33,000+

Recent Advances in Drug Development and Regulatory Science in China.

As the second largest pharmaceutical market with a great potential for future growth, China has drawn much attention from the global pharmaceutical community. With an increasing government investment in biomedical research, the domestic biopharmaceutical (biotechnological) companies in China are turning their attention to the development of innovative medicines and targeting the global market. To introduce innovative products to Chinese patients sooner, to improve the efficiency of its review and approval p...


Genetic diversity of porcine circovirus type 2 in China between 1999-2017.

Porcine circovirus type 2 (PCV-2), is linked to PCV-2 associated disease, which has caused considerable economic loss in the swine industry. Here, we report the genetic diversity of PCV-2 in China. A total of 74 Chinese PCV-2 strains sequenced between 1999 and 2017 were studied. Based on the ORF2 and complete genomes, we found that apart from the PCV-2a, PCV-2b, and PCV-2d genotypes, two unstable recombination genotypes also exist, referred to as IM1 and IM2 genotypes. We found that the patterns of PCV-2 ge...

miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.

The use of imatinib mesylate has greatly improved the clinical outcome for gastrointestinal stromal tumor (GIST) patients. However, imatinib resistance is still a major clinical challenge, and the molecular mechanisms are not fully understood. We have previously shown that miR-125a-5p and its mRNA target PTPN18 modulate imatinib response in GIST cells. Herein, we evaluated phosphorylated FAK (pFAK) as a candidate downstream target of PTPN18 and the possible association of this regulation with imatinib resis...


Hyaluronated Imatinib Liposomes with Hybrid approach to Target CD44 and P-gp Overexpressing MDR Cancer: An In-vitro, In-vivo and Mechanistic Investigation.

Multi Drug Resistance (MDR) of cancer cells is a constant threat to the clinically used drugs as well as new drug development. In present, work we aimed to assess in-vitro as well as in-vivo efficacy of the developed Imatinib loaded liposomes in MDR cancer. An array of tests was also carried out to comprehensively understand the bio-mechanism that enable these nanocarriers to modulate P-gp activity. Hyaluronic acid coated, Imatinib mesylate containing lipsomes (HA-LIPO-IM) were analysed through in-vitro and...

Bibliometric analysis of global publications in medication adherence (1900-2017).

Medication non-adherence is a worldwide problem. The aim of this study was to assess the global research output, research trends and topics that shaped medication adherence research.

Revisiting Trends in Augmented Reality Research: A Review of the 2nd Decade of ISMAR (2008-2017).

In 2008, Zhou et al. presented a survey paper summarizing the previous ten years of ISMAR publications, which provided invaluable insights into the research challenges and trends associated with that time period. Ten years later, we review the research that has been presented at ISMAR conferences since the survey of Zhou et al., at a time when both academia and the AR industry are enjoying dramatic technological changes. Here we consider the research results and trends of the last decade of ISMAR by careful...

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.

The use of generic drugs after patent expiration of their originators is a relative novelty in the treatment of chronic cancer patients in Western countries. In this observational study we analyzed a cohort of 294 Italian chronic phase chronic myeloid leukemia patients treated frontline with branded imatinib (Glivec®) for at least 6 months and then uniformly switched to generic imatinib upon requirement of health authorities in early 2017. Median age at diagnosis was 57 years (range 19-87). Sokal risk was ...

Implications of Medical Tourism.

Medical tourism is an emerging industry that facilitates travel to another country for people who seek medical, surgical, or dental care that is unavailable or more affordable than in their home countries. Rapid advances in electronic communication and the ease of international travel have fueled the growth of this industry. More than half of medical travelers are women, especially for services related to cosmetic or reproductive conditions. Medical tourism creates both opportunities and challenges for nurs...

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Global development goals increasingly rely on country-specific estimates for benchmarking a nation's progress. To meet this need, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 estimated global, regional, national, and, for selected locations, subnational cause-specific mortality beginning in the year 1980. Here we report an update to that study, making use of newly available data and improved methods. GBD 2017 provides a comprehensive assessment of cause-specific mortality for 2...

General Component Analysis (GCA): A new approach to identify Chinese corporate bond market structures.

PCA has been widely used in many fields to detect dominant principle components, but it ignores the information embedded in the remaining components. As a supplement to PCA, we propose the General Component Analysis (GCA). The inverse participation ratios (IPRs) are used to identify the global components (GCs) and localized components (LCs). The mean values of the IPRs derived from the shuffled data are taken as the natural threshold, which is exquisite and novel. In this paper, the Chinese corporate bond m...

Inhibition of STIM1-mediated SOCE as a novel strategy for the treatment of acquired imatinib-resistant GIST.

Imatinib has revolutionized the treatment of gastrointestinal stromal tumors (GIST); however, primary and secondary resistance to imatinib is still a major cause of treatment failure. Multiple mechanisms are involved in this progression. In the present study, we reported a novel mechanism for the acquired resistance to imatinib, which was induced by enhanced Ca2 influx via stromal-interacting molecule 1 (STIM1)-mediated store-operated Ca2 entry (SOCE). We found that the STIM1 expression level was related to...

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

The social issue in the BRICS Project.

BRICS, the acronym for Brazil, Russia, India, China and South Africa, is the first multilateral group created and run by non-western developed countries. The group aims to influence world geopolitics and market based on the right of developing and emerging countries to participate equitably in development. The social issue lies at the core of the group's justifications to achieve its goals. In this regard, this paper aims to analyze how the social issue has been addressed by BRICS. The methodology was based...

Erratum: Mapping the global influence of published research on industry and innovation.

Applying Corporate Political Activity (CPA) analysis to Australian gambling industry submissions against regulation of television sports betting advertising.

This research aimed to assess the application to the gambling industry, of Corporate Political Activity (CPA) analysis previously developed from public health research on tobacco industry interactions with political institutions and previously applied to the alcohol industry, but not the gambling industry.

Analysis of global stock index data during crisis period via complex network approach.

Considerable research has been done on the complex stock market, however, there is very little systematic work on the impact of crisis on global stock markets. For filling in these gaps, we propose a complex network method, which analyzes the effects of the 2008 global financial crisis on global main stock index from 2005 to 2010. Firstly, we construct three weighted networks. The physics-derived technique of minimum spanning tree is utilized to investigate the networks of three stages. Regional clustering ...

Prediction and elucidation of factors affecting solubilisation of imatinib mesylate in lipids.

The physico-chemical properties of lipids influencing the solubilisation of imatinib mesylate (IM) in lipid matrix were evaluated and a statistical model to predict the same has been derived in the present study. After experimental quantification of IM solubility in various lipids, Hansen Hildebrand's total solubility parameters were calculated in order to study the role of various forces connected to lipid-drug interaction. To develop a relationship between the various descriptors of the lipids and experim...

Tobacco industry denormalisation beliefs in Hong Kong adolescents.

Tobacco industry denormalisation (TID) seeks to expose the industry's misconducts. Research on TID beliefs, meaning negative attitudes towards the tobacco industry (TI), may inform TID programmes, but was limited to western populations. We investigated TID beliefs and their association with smoking and sociodemographic characteristics in Hong Kong adolescents.

Global Emergency Medicine: A review of the literature from 2017.

The Global Emergency Medicine Literature Review (GEMLR) conducts an annual search of peer-reviewed and gray literature relevant to global emergency medicine (EM) to identify, review, and disseminate the most important new research in this field to a global audience of academics and clinical practitioners.

Breast Cancer Research in the Caribbean: Analysis of Reports From 1975 to 2017.

Breast cancer is among the leading causes of death resulting from cancer in Caribbean women. Studies examining exogenous and genetically predetermined endogenous risk factors are critical to define breast cancer susceptibility in Caribbean women. The purpose of this systematic review is to assess the existing scientific literature in the last 42 years (1975 to 2017) to describe the body of research generated for the population of this region and determine future research directions.

Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.

The majority of available data on the clinical efficacy of sunitinib in patients with imatinib-resistant or -intolerant gastrointestinal stromal tumours (GISTs) are from studies of western populations. We investigated the clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure Asian GIST patients to further guide clinical treatment.

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the deadline. Although a majority of the draft guidelines regulating this process were already known in 2014 and 2015, the anticipated process itself caused anxiety among representatives of the foreign pharma industry, who tried to prepare for coming challenges. Among other possible issues, the ambiguity of transition...

IMATINIB-LOADED MICELLES OF HYALURONIC ACID DERIVATIVES FOR THE POTENTIAL TREATMENT OF NEOVASCULAR OCULAR DISEASES.

In this work, new micellar systems able to cross corneal barrier and to improve the permeation of imatinib free base were prepared and characterized. HA-EDA-C16, HA-EDA-C16-PEG and HA-EDA-C16-CRN micelles were synthesized starting from hyaluronic acid (HA), ethylenediamine (EDA), hexadecyl chains (C16), polyethylene glycol (PEG) and/or L-carnitine (CRN). These nanocarriers showed optimal particle size and mucoadhesive properties. Imatinib-loaded micelles were able to interact with corneal barrier and to pro...

Internationalization of Traditional/Complementary Medicine products: market entry as medicine.

Internationalization of Traditional/Complementary Medicine (T&CM) products is important for initiating and sustaining developments in this field. Particularly for traditional Chinese medicines (TCMs), the global market continues to expand due to an interest in the potential clinical benefits of traditional approaches that are largely considered lower risk and lower cost than many conventional treatments. While the benefits of internationalization hold clear advantages for the business of T&CM products, keep...

What to Know About Medicines With New Active Ingredients Approved in FY 2016 / 2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016.

The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and the European Medicines Agency (EMA) have a long-standing experience of reviews of new medicines, and they meet their target pre-market review periods. In FY 2016 / 2016, 112 and 83 new medicines were approved in Japan and EU, respectively. Out of these medicines, 41 and 27 medicines containing new active ingredients were approved with total pre-market review periods of 209 days and 428 days in Japan and EU, respectively. Approximately one-th...


Advertisement
Quick Search
Advertisement
Advertisement